<DOC>
	<DOC>NCT00380601</DOC>
	<brief_summary>An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA</brief_summary>
	<brief_title>PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Diagnosed as having RA, on the basis of the criteria stipulated by the American Conference on Rheumatism(ACR) in 1987 Active RA despite at least one DMARDs or immunosuppressants or Infliximab or Etanercept.Active disease is defined as having at least 6 tender and 6 swollen joints among DAS28 (Modified Disease Activity Scores that include twenty eight joint counts) and ESR at least 30 mm/hr or CRP not less than 2.0mg/dL Active RA despite over 10mg adrenocortical steroids within 2 weeks before entry of this study Shown to have classⅣ Steinbrocker's functional activity in an evaluation carried out within 4 weeks before administration of the study drug Treated with Infliximab within 3 months before and with Etanercept within 2 weeks before administration of the study drug Subjected to any of the following within 4 weeks before administration of the study drug: 1. Surgical treatment (operations,etc.). 2. Plasma exchange method</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>